Sigyn Therapeutics, Inc. has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive expertise in medical technology and extracorporeal therapies to advance the company's cardiovascular disease treatment development. Dr. Zaba's background includes directing global product management in therapeutic apheresis at Fresenius Medical Care, where he worked on immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for removing pathogenic lipoproteins from blood.
Lipoprotein apheresis, an established extracorporeal treatment methodology, reduces lipoprotein(a) and low-density lipoprotein cholesterol in the bloodstream. Clinical studies have demonstrated that this approach can reduce major adverse cardiovascular events by 55% to 98%, addressing cardiovascular disease as the leading cause of global deaths. However, treatment access remains limited to fewer than 60 specialized apheresis centers in the United States.
Sigyn Therapy represents a significant advancement as a whole blood adsorption technology designed to reduce both Lp(a) and LDL-C while simultaneously targeting inflammatory molecules that drive cardiovascular disease progression. The technology's design for use on existing dialysis machines located in approximately 7,500 U.S. dialysis clinics could dramatically expand treatment accessibility compared to current limited options.
The company recently disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy in high-risk cardiovascular disease subjects with end-stage renal disease. Successful completion of this study could lead to a pivotal efficacy study necessary for potential market clearance to treat cardiovascular disease. More information about the company's scientific advisory board can be found at https://www.sigyntherapeutics.com/about/scientific-advisory-board.
This appointment and technology development matter because cardiovascular disease remains the world's leading cause of death, and current treatment options using lipoprotein apheresis are severely limited by accessibility constraints. The potential to utilize existing dialysis infrastructure could transform treatment availability for millions of patients worldwide while addressing multiple cardiovascular risk factors simultaneously through a single therapeutic approach.
